Test-and-treat authority describes a regulatory pathway that combines two functions: administering a point-of-care diagnostic test and then acting on the result to initiate an appropriate course of therapy, all without requiring a separate visit to another prescriber. It has become one of the more visible examples of expanded pharmacist practice authority, typically built around specific, narrowly defined conditions rather than open-ended diagnosis.
Because it authorizes both testing and a treatment response, test-and-treat programs usually rest on more than one layer of state approval — a statute or board rule permitting the testing itself, plus a mechanism (a statewide protocol, standing order, or collaborative agreement) that grants the associated prescribing authority. The specific conditions covered, and the protocol a pharmacist must follow, are set entirely by state law.
Why it matters
A pharmacist who is authorized to test-and-treat in one state has no guarantee of the same authority elsewhere — some states have adopted broad statewide protocols, others authorize it only through individual collaborative agreements, and some don’t authorize it at all. This makes test-and-treat authority a key variable for any pharmacist evaluating what clinical services they can legally offer in a given state.
This entry describes the authorization mechanism only, not clinical guidance for any condition. RxByState tracks which states authorize test-and-treat services and how at https://app.rxbystate.com/signup.